bpc-157 human clinical trial dosing trials dosage BPC-157 (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or BPC-157, Healing angel or experimental
Description
These are research topics areas studies have explored, not promises about what it will do for any person
Unlike many peptides that are studied primarily for a single biological function, GHK-Cu has been examined across a broad spectrum of cellular processes
Kopycinski, J
BPC-157 isnt approved for fertility treatment by leading agencies and its still considered experimental, which significantly impacts study design, funding, and ethical oversight for human trials
Once reconstituted, store the solution at 2-8C, protect it from light, and prepare aliquots to avoid repeated freeze-thaw cycles
